In order to promote the improvement of clinical diagnosis, treatment and scientific research level of liver fibrosis and cirrhosis in China, the Seventh National Academic Conference on liver fibrosis and cirrhosis will be held in Lanzhou, Gansu Province from August 24 to 26, 2018, sponsored by the Chinese Medical Association and the hepatology branch of the Chinese Medical Association and hosted by the liver fiber chemistry group of the hepatology branch of the Chinese Medical Association.
Is antiviral enough for liver fibrosis and cirrhosis?
On the afternoon of August 25, Professor Jia Jidong of Beijing Friendship Hospital Affiliated to Capital Medical University and Professor Dou Xiaoguang of Shengjing Hospital Affiliated to China Medical University presided over the meeting. The chairman designate of liver disease credit association of Chinese Medical Association and Professor Xu Xiaoyuan of the first hospital of Peking University gathered in Lanzhou and launched a wonderful academic storm on this content. Take care of each other sincerely, and the platform will webcast this symposium.
The meeting was presided over by Professor Jia Jidong and Professor Dou Xiaoguang. Professor Xu Xiaoyuan made an academic report on "new progress of Anluo chemical fiber in the treatment of liver fibrosis and liver cirrhosis", which introduced the formation process of liver fibrosis in detail. Professor Xu stressed that antiviral treatment can not solve all problems. After 3-5 years of antiviral treatment, liver fibrosis has only partially improved. Anti fibrosis treatment is the key link to control the progress of liver disease. During the treatment of severe liver, timely anti fibrosis intervention can reduce the occurrence of necrotizing liver cirrhosis.
In his report, Professor Xu introduced the major special project of the 12th Five Year Plan led by Professor Wang GuiQiang of the first hospital of Peking University - the research on the reversal of liver fibrosis / sclerosis by entecavir (ETV) combined with Anluohuaxian pill (alhq). It is also the first large sample, randomized controlled trial to improve liver fibrosis in patients with hepatitis B liver fibrosis.
As for the mechanism of Anluohuaxian pill, academician Zhuang Hui's team has confirmed that Anluohuaxian can significantly inhibit TGF β 1 and the corresponding Smads signal pathway, so as to inhibit the activation of stellate cells (HSC) and play an anti fibrosis role.
In view of the above advantages, Anluohuaxian pill was recently included in the major scientific and technological projects of the 13th five year plan. The project was launched in Beijing on January 29, 2018, and included many guidelines, consensus and general rules at the same time
As for the mechanism of Anluohuaxian pill, academician Zhuang Hui's team has confirmed that Anluohuaxian can significantly inhibit TGF β 1 and the corresponding Smads signal pathway, so as to inhibit the activation of stellate cells (HSC) and play an anti fibrosis role.
In view of the above advantages, Anluohuaxian pill was recently included in the major scientific and technological projects of the 13th five year plan. The project was launched in Beijing on January 29, 2018, and included many guidelines, consensus and general rules at the same time
In conclusion, Professor Dou Xiaoguang said: Anluo chemical fiber supports the research of the 12th Five Year Plan and the 13th five year plan, gives us clinicians confidence in medication, and hopes that doctors can use this drug better in clinic to benefit patients.
Traditional Chinese medicine is a treasure house of wisdom inherited by the motherland for a long time and should be used reasonably. In recent years, there are more and more studies on the treatment of liver fibrosis by traditional Chinese medicine, and the unique advantages of traditional Chinese medicine are becoming more and more obvious. At present, the control of antiviral therapy on the progress of liver fibrosis is still not ideal. The research and development of anti fibrosis drugs has become a hot spot in the field of liver disease treatment. I believe that with the full cooperation of the majority of peers, China's progress in anti hepatic fibrosis treatment will make more achievements! (treating each other with sincerity - online public service platform for hepatobiliary diseases www.igandan. Com)
Handan Institute of liver diseases
